October 2021 OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’
October 2021 OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of OSE-127
October 2021 OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3
October 2021 OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®
October 2021 OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea
October 2021 OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor